KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Inventory (2016 - 2026)

Amgen has reported Inventory over the past 18 years, most recently at $6.2 billion for Q1 2026.

  • For Q1 2026, Inventory fell 8.07% year-over-year to $6.2 billion; the TTM value through Mar 2026 reached $6.2 billion, down 8.07%, while the annual FY2025 figure was $6.2 billion, 11.05% down from the prior year.
  • Inventory for Q1 2026 was $6.2 billion at Amgen, down from $6.2 billion in the prior quarter.
  • Over five years, Inventory peaked at $9.5 billion in Q4 2023 and troughed at $4.4 billion in Q1 2022.
  • A 5-year average of $6.3 billion and a median of $6.2 billion in 2025 define the central range for Inventory.
  • Biggest five-year swings in Inventory: skyrocketed 93.06% in 2023 and later decreased 26.48% in 2024.
  • Year by year, Inventory stood at $4.9 billion in 2022, then skyrocketed by 93.06% to $9.5 billion in 2023, then decreased by 26.48% to $7.0 billion in 2024, then dropped by 11.05% to $6.2 billion in 2025, then fell by 0.63% to $6.2 billion in 2026.
  • Business Quant data shows Inventory for AMGN at $6.2 billion in Q1 2026, $6.2 billion in Q4 2025, and $6.3 billion in Q3 2025.